Duchenne muscular dystrophy

Amazing landscapes of Appenzell with impressive rock formations and beautiful lakes
Biotech

Dyne readies FDA push after DMD exon 51 med excels in trial

The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement.
Eric Sagonowsky Dec 8, 2025 10:50am
sarepta building
Favicon Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Nov 4, 2025 7:56am
Goal disorientation and lack of vision

UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss

Jul 8, 2025 10:17am
Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Jun 16, 2025 10:58am
The Top Line

What were the biggest clinical trial flops of 2024?

Feb 21, 2025 9:00am
rocket ship blast off fire away take off

Solid soars as early DMD gene therapy data beat expectations

Feb 18, 2025 8:10am